Whole-cell vaccine candidates induce a protective response against virulent Acinetobacter baumannii
Abstract
Acinetobacter baumannii causes multi-system diseases in both nosocomial settings and a pre-disposed general population. The bacterium is not only desiccation-resistant but also notoriously resistant to multiple antibiotics and drugs of last resort including carbapenem, colistin, and sulbactam. The World Health Organization has categorized carbapenem-resistant A. baumannii at the top of its critical pathogen list in a bid to direct urgent countermeasure development. Several early-stage vaccines have shown a range of efficacies in healthy mice, but no vaccine candidates have advanced into clinical trials. Herein, we report our findings that both an ionizing γ-radiation-inactivated and a non-ionizing ultraviolet C-inactivated whole-cell vaccine candidate protects neutropenic mice from pulmonary challenge with virulent AB5075, a particularly pathogenic isolate. In addition, we demonstrate that a humoral response is sufficient for this protection via the passive immunization of neutropenic mice.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 27, 2022
- Source ID
- 10.3389/fimmu.2022.941010
Entities
People
- Christine M. Czintos
- Daniel V Zurawski
- David A. Macleod
- Gregory J. Tobin
- Heather N. Meeks
- John K. Tobin
- Mariel G. Escatte
- Michael J. Daly
- Naomi J. P. E. R. Tasker
- Rania Abu-taleb
- Ruth V. Bushnell
- Stephen J Dollery
- Taralyn J. Wiggins
- Wanwen Su
- Yonas A. Alamneh
Organizations
- Defense Threat Reduction Agency